Mounjaro contraindications: the full picture before you start

The biggest myth: that almost anyone with a health condition is ruled out

A question our prescribers hear most weeks is some version of: "I've got [condition], does that mean I can't take Mounjaro?" The assumption is that the contraindication list is long and sweeping. In reality, the UK Summary of Product Characteristics lists only two absolute contraindications for tirzepatide: a personal or family history of medullary thyroid carcinoma, and Multiple Endocrine Neoplasia syndrome type 2. Both relate to the thyroid tumour signal observed in rodent studies; while that signal has not been confirmed in humans, the licensing authorities rightly excluded this group from use until evidence is clearer.

Outside those two, most conditions sit in the category of precautions: things the prescriber must weigh, not things that automatically disqualify you. Knowing which bucket your situation falls into is the point of the clinical assessment, not a formality but a genuine medical conversation. The full guide to Mounjaro as a medicine covers the broader picture of how treatment works and who it is designed for.

If you have been told online that conditions like type 2 diabetes, high blood pressure or mild kidney disease are contraindications to Mounjaro, that is not accurate. They may require closer monitoring, but they are not barriers, and in some cases they are part of the eligibility criteria.

The absolute contraindications to tirzepatide, and why they exist

Two situations are absolute contraindications in the UK product information. First: a personal or family history of medullary thyroid carcinoma. MTC is a rare cancer arising from the thyroid's C-cells, which respond to GLP-1 and GIP signals. Animal studies showed increased thyroid tumour rates at sustained high doses; the clinical relevance in humans is not established, but the MHRA-approved label excludes anyone with MTC history or a first-degree relative with it. Second: Multiple Endocrine Neoplasia type 2, a hereditary syndrome that strongly predisposes to MTC. If MEN2 is in your history, tirzepatide is not appropriate regardless of weight or other factors.

Hypersensitivity to tirzepatide or to any excipient in the pen is also listed; a severe allergic reaction to a previous dose means treatment should not be restarted without specialist input. These are the only situations where the answer is a firm no before any further assessment. If you want to understand where tirzepatide sits among the wider family of GLP-1 medications and how tirzepatide differs from them, that context can help clarify why these particular contraindications apply. The BNF entry for tirzepatide sets these out clearly for prescribers, alongside the full interactions and cautions list, available at bnf.nice.org.uk.

It is also worth noting that Mounjaro is not licensed for anyone under 18, so age is an additional absolute limit, though this is a licensing boundary rather than a contraindication in the clinical sense.

Precautions that require clinical judgement, not automatic exclusion

A longer list of conditions calls for careful prescriber assessment without ruling Mounjaro out entirely. History of pancreatitis sits prominently here. Tirzepatide (like all GLP-1-class medicines) has been associated with acute pancreatitis as an infrequent but potentially serious event. Severe, persistent abdominal pain that spreads to the back is the warning sign; anyone who develops it needs urgent medical attention. For those with a previous episode of pancreatitis, a prescriber will weigh the risk against the benefit on an individual basis. The NHS page on Mounjaro and abdominal pain covers what to watch for once treatment starts.

Gallbladder disease is another precaution: rapid weight loss can accelerate gallstone formation, and pre-existing gallbladder problems may be aggravated. Severe gastrointestinal conditions (including gastroparesis or severe inflammatory bowel disease) require discussion because Mounjaro slows gastric emptying, which could worsen those conditions. Diabetic retinopathy is flagged for people with type 2 diabetes because rapid improvements in blood-sugar control can temporarily worsen certain eye conditions; ophthalmological monitoring is recommended in those cases.

Renal and hepatic impairment sit in the precaution category. Mild-to-moderate kidney disease does not disqualify use, but the prescriber monitors more closely; severe impairment requires careful individual assessment. Heart failure and a history of significant cardiovascular events are weighed in context rather than treated as barriers, Mounjaro's licence actually includes adults with cardiovascular risk factors as part of its eligible population. The full indications for Mounjaro in the UK explains exactly which populations the medicine is licensed to treat.

Contraception, pregnancy and situations that change over time

Mounjaro is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. These are not contraindications in the formal SmPC sense, there is simply not enough human safety data, and animal studies raised concerns. Anyone planning to become pregnant should discuss stopping treatment with their prescriber well in advance.

The contraception point catches people off guard. Mounjaro slows gastric emptying, and for the first four weeks of treatment (and for four weeks after each dose increase) oral contraceptives may be absorbed less reliably. UK clinical guidance recommends adding a non-oral method (such as condoms) during those windows, or switching to a patch, implant or injection. This does not mean oral contraceptives become a contraindication; it means an adjustment is needed. The NHS information page on tirzepatide covers this alongside other key safety points in plain language.

Drug interactions can also shift the clinical picture, and our guidance on Mounjaro and other medications is a useful starting point before the prescriber checks your full medication list for combinations that need particular care, including how Mounjaro's effect on gastric emptying may alter the absorption timing of other oral medicines taken at the same dose time, with our dedicated page on Mounjaro medication interactions going into detail on which combinations need particular care.

If you are thinking about whether Mounjaro could suit your situation, the right place to start is a clinical conversation. Check your eligibility with our prescribers, it's free, there's no obligation, and the same-day review means you get a proper clinical answer quickly rather than an algorithm's guess.